Exon 1 ss of pdgf alpha gene and utilization thereof

/Home/Lyophilization and Protein Formulation Patents/Patents - Biologics/European Patents - Biologics

Exon 1 ss of pdgf alpha gene and utilization thereof
Publication number: US2006211638
Publication date: 2006-09-21
Inventor: IMOTO MASAYA (JP); MINATO YUSUKE (JP); TASHIRO ETSU (JP)
Applicant:
Classification:
- international: A61K48/00; A61K31/7088; A61P35/00; A61P43/00; C07H21/02; C12N15/11; C12N15/12; C12N15/87; A61K48/00; A61K31/7088; A61P35/00; A61P43/00; C07H21/00; C12N15/11; C12N15/12; C12N15/87;
- european: A61K31/7088; C12N15/11B7
Application number: US20060534836 20060216
Priority number(s): JP20020332142 20021115; WO2003JP14528 20031114

Also published as:
EP1574574 (A1)
WO2004046356 (A1)
CN1729291 (A)
CA2506245 (A1)
AU2003302135 (A1)

Abstract of US2006211638

By using an antisense nucleotide, a ribozyme, a maxizyme, or an RNAi constructed based on the nucleotide sequence of exon 1 beta of the PDGF receptor alpha gene, which is expressed in specific cancer cells, or a polypeptide containing a portion thereof, translation of an mRNA transcribed from exon 1 beta of the PDGF receptor alpha gene is suppressed. An agent for suppressing expression containing as an active ingredient a substance for inhibiting expression, such as an antisense nucleotide, a ribozyme, a maxizyme, or an RNAi, is effective as a therapeutic agent for cancer.